Abstract:Due to the COVID‐19 pandemic, a series of sequelae, such as fatigue, tachypnea and ageusia, appeared in long COVID patients, but the pathological basis was still uncertain. The targeted radiopharmaceuticals were of potentials to systemically and dynamically trace the pathological changes. For the key ACE2 protein in the virus‐host interaction, 68Ga‐cyc‐DX600 was developed on the basis of DX600 as a PET tracer of ACE2 fluctuation, and maintained the ability in differentiating ACE and ACE2. In the temporary infection model inhaled with the radio‐traceable pseudovirus in the upper respiratory of male humanized ACE2 (hACE2) mice, organ‐specific ACE2 dysfunction in acute period and the following ACE2 recovery in a relatively long period were visualized and quantified by ACE2 PET, revealing a complex pattern of virus concentration‐dependent degree and time period‐dependent tendency of ACE2 recovery, mainly a sudden decrease of apparent ACE2 in heart, liver, kidneys, lungs and so on, but liver was of a quick functional compensation on ACE2 expression after a temporary decrease. ACE2 expression of most organs has recovered to a normal level at 15 days P.I., with brain and genitals still of a decreased SUVACE2, meanwhile, kidneys were of an increased SUVACE2. These findings on ACE2 PET were further verified by western blot. When compared with high‐resolution computed tomography on structural changes and FDG PET on glycometabolism, ACE2 PET was of the superiority on earlier diagnostic window during infection and more comprehensive understanding of functional dysfunction post infection. In the respective ACE2 PET/CT and ACE2 PET/MR scans of a volunteer, the repeatability of SUVACE2 and the ACE2 specificity were further confirmed. In conclusion, 68Ga‐cyc‐DX600 was developed as an ACE2‐specific tracer, and the corresponding ACE2 PET revealed the dynamic patterns of functional ACE2 recovery and provided a reference and approach to explore the ACE2‐related pathological basis of sequelae in long COVID. This article is protected by copyright. All rights reserved.

An Auger electron-loaded theranostic biosensor triggered by the ACE2-mediated virus/host endocytosis

Evaluation of Angiotensin-Converting Enzyme 2 Expression In Vivo with Novel 68Ga-Labeled Peptides Originated from the Coronavirus Receptor-Binding Domain

Preclinical Evaluation and Pilot Clinical Study of 18F-Labeled Inhibitor Peptide for Noninvasive Positron Emission Tomography Mapping of Angiotensin Converting Enzyme 2

Auger Radiation-Induced, Antisense-Mediated Cytotoxicity Of Tumor Cells Using A 3-Component Streptavidin-Delivery Nanoparticle With In-111

Radiotracers for Molecular Imaging of Angiotensin-Converting Enzyme 2

SARS-CoV-2 receptor binding domain radio-probe: a non-invasive approach for angiotensin-converting enzyme 2 mapping in mice

ACE2 PET to Reveal the Dynamic Patterns of ACE2 Recovery in an Infection Model with Pseudo Corona Virus

Genetically Engineered Virus-Like Particle-Armoured and Multibranched DNA Scaffold-Corbelled Ultra-Sensitive Hierarchical Hybridization Chain Reaction for Targeting-Enhanced Imaging in Living Biosystems under Spatiotemporal Light Powering

Engineering a NanoBiT biosensor for detecting angiotensin-converting enzyme-2 (hACE2) interaction with SARS-CoV-2 spike protein and screening the inhibitors to block hACE2 and spike interaction

Seeing is believing: Efficiency evaluation of multifunctional ionic-dependent AIEgens for tuberculosis

ACE2 PET to Reveal the Dynamic Patterns of ACE2 Recovery in an Infection Model with Pseudocorona Virus.

Mitochondria-targeting nanozyme for catalytical therapy and radiotherapy with activation of cGAS-STING

Precision Fluorescent Labeling of an Adeno-Associated Virus Vector to Monitor the Viral Infection Pathway.

Preclinical Evaluation and Pilot Clinical Study of Al18F-DX600-BCH for non-invasive PET Mapping of Angiotensin Converting Enzyme 2 in Mammal

Sono-Immunotherapeutic Nanocapturer to Combat Multidrug-Resistant Bacterial Infections

Protease-Responsive Peptide-Conjugated Mitochondrial-Targeting AIEgens for Selective Imaging and Inhibition of SARS-CoV-2-Infected Cells

Enhanced real-time monitoring of adeno-associated virus trafficking by virus-quantum dot conjugates.

Molecular PET/CT mapping of rhACE2 distribution and quantification in organs to aid in SARS-CoV-2 targeted therapy.

Combination of bacterial-targeted delivery of gold-based AIEgen radiosensitizer for fluorescence-image-guided enhanced radio-immunotherapy against advanced cancer

Molecular PET/CT mapping of rhACE2 distribution and quantification in organs to aid in SARS-CoV-2 targeted therapy

Programmable Proteolysis-Activated Transcription for Highly Sensitive Ratiometric Electrochemical Detection of Viral Protease